FDA accepts AstraZeneca’s BLA review for tremelimumab to treat HCC
The move supports the indication of a single priming anti-CTLA4 antibody dose added to the human monoclonal antibody Imfinzi (durvalumab) to treat HCC patients. AstraZeneca also submitted a